Alvotech

Alvotech is a global biotechnology company singularly focused on the development and manufacture of biosimilar medicines. Founded in 2013, its mission is to improve patient health and quality of life by expanding access to high-quality, affordable biologic medicines worldwide. The company's operational headquarters, including its state-of-the-art research, development, and cGMP manufacturing facility, are located in Reykjavik, Iceland, while its legal entity is registered in Luxembourg.

Alvotech boasts a robust portfolio of biosimilar candidates targeting significant therapeutic areas such as immunology, oncology, and ophthalmology. Key commercialized products include biosimilars to Humira (AVT02), Stelara (AVT04), Simponi/Simponi Aria (AVT05), Eylea (AVT06), and Prolia/Xgeva (AVT03). The company leverages a fully integrated platform, encompassing everything from cell line development to commercial manufacturing, and collaborates with strategic partners for global distribution.

In recent news, Alvotech successfully completed a public offering and concurrent private placement in June 2026, raising approximately $165 million to fund its biosimilar pipeline and general corporate purposes. The company also announced the FDA's acceptance of its Biologics License Application for AVT16, a proposed biosimilar to Entyvio, and the resubmission of applications for AVT05 and AVT06. Lisa Graver was appointed CEO in March 2026, succeeding founder Robert Wessman, who continues to serve as Executive Chairman.